Summit Therapeutics Inc vs NEOS S&P 500 High Income ETF — how do they compare? Summit Therapeutics Inc trades at $14.58 (market cap $10.48B), while NEOS S&P 500 High Income ETF trades at $53.45. The key difference: NEOS S&P 500 High Income ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| SMMT | SPYI | |
|---|---|---|
Market Cap | $10.48B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $29.32 | $54.07 |
52-Week Low | $13.05 | $47.98 |
Enterprise Value | $9.90B | — |
Trailing returns across standard periods
Latest headlines on both assets
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →SPYI is an actively managed ETF designed to generate high monthly income through a data-driven call option strategy on the S&P 500 Index. Unlike traditional covered call funds that often forfeit significant upside, SPYI utilizes a 'call spread' approach—selling near-the-money calls while buying out-of-the-money calls—to capture a portion of equity appreciation in rising markets. It prioritizes tax efficiency by utilizing Section 1256 contracts and tax-loss harvesting to provide investors with high-yield monthly distributions.
Read more on SPYI →